Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists - Madsbad - 2016 - Diabetes, Obesity and Metabolism - Wiley Online Library
Victoza® (liraglutide) injection 1.2 mg or 1.8 mg Mechanism of Action
The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg | Diabetology & Metabolic Syndrome | Full Text
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence | Nature Reviews Nephrology
Short‐acting glucagon‐like peptide‐1 receptor agonists as add‐on to insulin therapy in type 1 diabetes: A review - Albèr - 2017 - Diabetes, Obesity and Metabolism - Wiley Online Library
Effective Switch From Twice-Daily Pre-Mixed Insulin 50/50 to Liraglutide to Achieve a Good Glycemic Control in Type 2 Diabetes | Yanai | Journal of Medical Cases
The 10+ Benefits of Liraglutide — MyBioHack | Unlock Your Maximus Potential
Approaches for half-life extension of GLP-1 agonists. (a) Liraglutide... | Download Scientific Diagram
How Victoza® Works | Victoza® (liraglutide) injection 1.2 mg or 1.8 mg
Liraglutide Mechanism of Action for Weight Loss (Obesity) and Diabetes
Effects of liraglutide (GLP-1 receptor agonist) – Efficacy and Adverse... | Download Scientific Diagram
GLP-1 analogs
Oral and Injectable (Non-Insulin) Pharmacological Agents for the Treatment of Type 2 Diabetes - Endotext - NCBI Bookshelf
Victoza (Liraglutide [rDNA] Injection): Uses, Dosage, Side Effects, Interactions, Warning
Liraglutide is neurotrophic and neuroprotective in neuronal cultures and mitigates mild traumatic brain injury in mice - Li - 2015 - Journal of Neurochemistry - Wiley Online Library
Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension | Arteriosclerosis, Thrombosis, and Vascular Biology